- Biopharma layoffs must double in H2 for 2026 to match 2025 cutsWith fewer biopharmas making or planning workforce reductions so far year over year, layoff round size and M&A impact on headcounts will likely shape the number of employees who are ultimately on t…BioSpace · 4d ago↗ source
- Recon: J&J nabs FDA authorization for general surgery robot; FDA urged to ban DTC drug ads<p>Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.</p>raps · 4d ago↗ source
- Euro Roundup: EMA seeks feedback on planned changes to guidance on biosimilar efficacy studies<p>The European Medicines Agency (EMA) has released a draft concept paper on planned changes to its guideline on similar biological medicinal products.</p>